{
    "ticker": "UTHR",
    "name": "United Therapeutics Corporation",
    "description": "United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet needs of patients with chronic and life-threatening conditions. Founded in 1996 by Dr. Martine Rothblatt, the company is a leader in the field of pulmonary arterial hypertension (PAH) and organ transplantation. United Therapeutics is known for its innovative therapies, including Remodulin, Tyvaso, and Orenitram, which are designed to improve the quality of life for patients suffering from PAH. In addition to its commitment to treating PAH, the company is actively engaged in groundbreaking work in organ preservation, regenerative medicine, and xenotransplantation, with the aim of addressing the critical shortage of available organs for transplant. United Therapeutics is dedicated to advancing science and technology to improve patient outcomes, and it collaborates with various research institutions and organizations to further its mission. With a strong emphasis on research and development, the company continues to explore new therapeutic areas and expand its portfolio of life-saving treatments.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Silver Spring, Maryland, USA",
    "founded": "1996",
    "website": "https://www.unither.com",
    "ceo": "Martine Rothblatt",
    "social_media": {
        "twitter": "https://twitter.com/UnitedTherapeutics",
        "linkedin": "https://www.linkedin.com/company/united-therapeutics/"
    },
    "investor_relations": "https://investors.unither.com",
    "key_executives": [
        {
            "name": "Martine Rothblatt",
            "position": "CEO"
        },
        {
            "name": "Sharon D. Mates",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Pulmonary Arterial Hypertension Treatments",
            "products": [
                "Remodulin",
                "Tyvaso",
                "Orenitram"
            ]
        },
        {
            "category": "Organ Preservation and Transplantation",
            "products": [
                "Xenotransplantation Products"
            ]
        }
    ],
    "seo": {
        "meta_title": "United Therapeutics Corporation | Biotechnology and Pharmaceuticals",
        "meta_description": "Explore United Therapeutics Corporation, a leader in biotechnology focused on innovative treatments for pulmonary arterial hypertension and organ transplantation.",
        "keywords": [
            "United Therapeutics",
            "Biotechnology",
            "Pulmonary Arterial Hypertension",
            "Organ Transplantation",
            "Martine Rothblatt"
        ]
    },
    "faq": [
        {
            "question": "What is United Therapeutics known for?",
            "answer": "United Therapeutics is known for its innovative treatments for pulmonary arterial hypertension and advancements in organ transplantation."
        },
        {
            "question": "Who is the CEO of United Therapeutics?",
            "answer": "Martine Rothblatt is the CEO of United Therapeutics Corporation."
        },
        {
            "question": "Where is United Therapeutics headquartered?",
            "answer": "United Therapeutics is headquartered in Silver Spring, Maryland, USA."
        },
        {
            "question": "What are United Therapeutics' main products?",
            "answer": "United Therapeutics' main products include Remodulin, Tyvaso, and Orenitram for PAH."
        },
        {
            "question": "When was United Therapeutics founded?",
            "answer": "United Therapeutics was founded in 1996."
        }
    ],
    "competitors": [
        "VRTX",
        "BMRN",
        "SNY",
        "ABBV"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "JNJ"
    ]
}